FibroBiologics Announces Closing of $3 Million Public Offering

FibroBiologics (NASDAQ: FBLG) closed a best-efforts public offering on April 2, 2026, selling 2,272,728 shares and warrants to purchase up to 2,272,728 shares at a combined public offering price of $1.32 per share and warrant.

Rhea-AI Summary

FibroBiologics (NASDAQ: FBLG) closed a best-efforts public offering on April 2, 2026, selling 2,272,728 shares and warrants to purchase up to 2,272,728 shares at a combined public offering price of $1.32 per share and warrant.

The offering generated approximately $3 million gross proceeds before fees; the Warrants carry a $1.32 exercise price and, if fully exercised, could provide an additional ~$3 million. Warrants become exercisable upon stockholder approval and expire five years after that date.

Positive

• Gross proceeds of approximately $3 million
• Warrants could raise an additional $3 million if fully exercised
• Offer priced at $1.32 per share and warrant

Negative

• Warrant exercise contingent on stockholder approval
• Immediate dilution from 2,272,728 shares issued
• No assurance that Warrants will be exercised

Argus Apr 6 session

-0.72% close to close Open Argus

Details

News Market Reaction – FBLG

On Apr 6, the first trading day after this news, FBLG closed 0.72% below the previous close.

Data tracked by StockTitan Argus for the Apr 6 session.

Key Figures

Patent portfolio: 270+ patents issued and pending Shares offered: 2,272,728 shares Warrants offered: 2,272,728 warrants +5 more

Patent portfolio

270+ patents issued and pending

Described company IP position

Shares offered

2,272,728 shares

Common stock (or equivalents) in public offering

Warrants offered

2,272,728 warrants

Warrants to purchase common stock in offering

Offering price

$1.32 per share plus warrant

Combined public offering price

Gross proceeds

approximately $3 million

Aggregate gross proceeds before fees

Potential warrant proceeds

approximately $3 million

If all warrants are fully exercised for cash

Warrant term

5 years

Expires on five-year anniversary of Stockholder Approval

Registration statement

Form S-1, File No. 333-294713

Offering registered under effective SEC filing

Previous Offering Reports

5 past events · Latest: Mar 31

Same Type 5 events

1. Mar 31

   $3M offering pricing

   24h Move

   +0.8%

   Priced best-efforts offering with common stock and warrants at $1.32.

2. Dec 16

   $1.7M offering close

   24h Move

   +14.5%

   Closed registered direct offering and private warrants for $1.7M gross.

3. Dec 15

   $1.7M offering announce

   24h Move

   -33.1%

   Announced registered direct offering and concurrent private placement of warrants.

4. Nov 25

   $1.5M offering close

   24h Move

   +1.5%

   Closed registered direct offering and concurrent warrants totaling $1.5M.

5. Nov 24

   $1.5M offering announce

   24h Move

   -23.5%

   Announced registered direct offering with matching warrant package for $1.5M.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

warrants, best efforts public offering, stockholder approval, registration statement on Form S-1, +4 more

8 terms

warrants financial

"and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”)"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

best efforts public offering financial

"closing of its previously announced best efforts public offering of an aggregate of 2,272,728 shares"

A best efforts public offering is a way a company sells new shares or bonds where the broker or bank agrees to try to sell as many securities as possible but does not promise to buy any unsold portion. Think of it like a salesperson taking items on consignment: they will work to sell them, but the seller bears the risk if some remain unsold. For investors, this matters because it can signal weaker demand and greater uncertainty about how many securities will actually be placed and how the price may move.

stockholder approval regulatory

"exercisable beginning on the effective date of stockholder approval of the issuance of the shares"

Stockholder approval is formal consent given by a company’s shareholders, usually through a vote at a meeting or by proxy, for major actions such as mergers, asset sales, changes to corporate structure, or amendments to governance rules. Investors pay attention because the vote can enable or block steps that materially change a company’s direction, ownership or value—like neighbors voting to allow a major renovation that would alter a building’s use and worth.

registration statement on Form S-1 regulatory

"offered pursuant to a registration statement on Form S-1 (File No. 333-294713)"

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering was made only by means of a prospectus forming part of the effective registration"

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

public offering price financial

"at a combined public offering price of $1.32 per share"

The public offering price is the amount of money a company charges investors to buy its shares during a new stock sale to the public. It determines how much the company raises and how much each share is worth at the start of trading. For investors, it helps gauge the initial value of the stock and whether it might be a good investment opportunity.

exercise price financial

"The Warrants have an exercise price of $1.32 per share and are exercisable"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

placement agent financial

"H.C. Wainwright & Co. acted as the exclusive placement agent for the offering."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced best efforts public offering of an aggregate of 2,272,728 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 2,272,728 shares of common stock (the “Warrants”), at a combined public offering price of $1.32 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants have an exercise price of $1.32 per share and are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the Warrants (the “Stockholder Approval”) and will expire on the five-year anniversary of the date of Stockholder Approval.

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $3 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The potential additional gross proceeds to the Company from the Warrants, if fully exercised on a cash basis, will be approximately $3 million. No assurance can be given that any of the Warrants will be exercised. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

The securities described above were being offered pursuant to a registration statement on Form S-1 (File No. 333-294713), which was declared effective by the Securities and Exchange Commission (the “SEC”) on March 31, 2026. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. Electronic copies of the final prospectus may be obtained on the SEC's website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About FibroBiologics, Inc.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the anticipated use of proceeds from the offering; the exercise of the Warrants prior to their expiration, and the receipt of Stockholder Approval. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption “Risk Factors” and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) the unpredictable relationship between R&D and preclinical results and clinical study results; (c) the ability of FibroBiologics to successfully prosecute its patent applications, (d) FibroBiologics’ ability to manufacture its product candidates; and (e) FibroBiologics’ ability to conduct clinical trials. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.

General Inquiries:
info@fibrobiologics.com

Investor Contact:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com

Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com  

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did FibroBiologics (FBLG) announce on April 2, 2026 about its public offering?

FibroBiologics closed a best-efforts public offering of 2,272,728 shares and matching warrants at $1.32 each. According to the company, the offering generated approximately $3 million gross proceeds before fees and expenses, with warrants exercisable after stockholder approval.

How many warrants did FibroBiologics (FBLG) issue and what is the exercise price?

FibroBiologics issued warrants to purchase up to 2,272,728 shares with a $1.32 exercise price. According to the company, the warrants mirror the share count and expire five years after stockholder approval, and may provide about $3 million if fully exercised.

When can holders exercise the FibroBiologics (FBLG) warrants and how long do they last?

Warrants become exercisable on the effective date of stockholder approval and expire five years later. According to the company, the exercise window begins only after shareholders approve issuance and the expiration is five years from that approval date.

What will FibroBiologics (FBLG) use the net proceeds from the offering for?

The company intends to use net proceeds for working capital and general corporate purposes. According to the company, proceeds are not earmarked for a specific program and will support ongoing operations and corporate needs following the offering.

Who acted as placement agent for FibroBiologics (FBLG) and where is the prospectus available?

H.C. Wainwright & Co. acted as exclusive placement agent for the offering. According to the company, the final prospectus is available on the SEC website and via H.C. Wainwright contact channels listed in the offering materials.

How much additional funding could FibroBiologics (FBLG) receive if all warrants are exercised?

If all warrants are exercised for cash, the company could receive approximately $3 million in additional gross proceeds. According to the company, this potential funding is contingent on warrant exercise and there is no assurance any warrants will be exercised.